Weiss Multi-Strategy Advisers’s Catalyst Pharmaceutical CPRX Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-30,000	Closed	-$76K	–	572
2017 Q3	$76K	Sell	30,000 -30,000	-50%	-$82.3K	﹤0.01%	467
2017 Q2	$166K	Sell	60,000 -8,000	-12%	-$16.7K	0.01%	497
2017 Q1	$133K	Hold	68,000	–	–	0.01%	524
2016 Q4	$71K	Hold	68,000	–	–	﹤0.01%	397
2016 Q3	$74K	Sell	68,000 -1,255	-2%	-$1.13K	﹤0.01%	404
2016 Q2	$49K	Sell	69,255 -52,745	-43%	-$42.5K	﹤0.01%	392
2016 Q1	$143K	Hold	122,000	–	–	0.01%	436
2015 Q4	$299K	Hold	122,000	–	–	0.02%	333
2015 Q3	$366K	Sell	122,000 -8,000	-6%	-$34.5K	0.02%	340
2015 Q2	$537K	Sell	130,000 -18,000	-12%	-$71.7K	0.02%	376
2015 Q1	$641K	Sell	148,000 -12,000	-8%	-$43.3K	0.03%	350
2014 Q4	$475K	Buy	160,000 +10,000	+7%	+$27.4K	0.02%	345
2014 Q3	$498K	Sell	150,000 -60,000	-29%	-$157K	0.01%	437
2014 Q2	$531K	Buy	210,000 +110,000	+110%	+$235K	0.01%	516
2014 Q1	$226K	Buy	+100,000	New	+$209K	﹤0.01%	886

Other funds holding CPRX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Weiss Multi-Strategy Advisers's CPRX Position: Q4 2017 in Review

Weiss Multi-Strategy Advisers sold out of Catalyst Pharmaceutical (CPRX) in Q4 2017, closing a stake of 30,000 shares — an estimated $76K sold.

Weiss Multi-Strategy Advisers first reported a position in CPRX in Q1 2014 and held it in 15 quarters. The position peaked at $641K in Q1 2015. 105 funds tracked by Wall St. Rank hold CPRX as of Q4 2017.

Weiss Multi-Strategy Advisers reported no remaining Catalyst Pharmaceutical position as of Q4 2017 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 30,000 Catalyst Pharmaceutical shares in Q4 2017, an estimated $76K.
Weiss Multi-Strategy Advisers first reported a position in Catalyst Pharmaceutical in Q1 2014 and held it in 15 quarters.
Weiss Multi-Strategy Advisers's Catalyst Pharmaceutical position peaked at $641K in Q1 2015.
105 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2017.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q4 2017, filed 14 Feb 2018.